Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

<ul>
<li>Cencora, in its fiscal 2025 fourth-quarter and full-year results call, reported strong financial performance supported by growth in its strategic initiatives and significant market trends.</li>
<li>The earnings call highlighted a 16% increase in both adjusted operating income and adjusted diluted earnings per share (EPS), driven by strategic investments in specialty areas and strong pharmaceutical utilization trends.</li>
<li>This performance underlines Cencora’s strategic role as an end-to-end healthcare services company.</li>
</ul>


Cencora, in its fiscal 2025 fourth-quarter and full-year results call, reported strong financial performance supported by growth in its strategic initiatives and significant market trends.
The earnings call highlighted a 16% increase in both adjusted operating income and adjusted diluted earnings per share (EPS), driven by strategic investments in specialty areas and strong pharmaceutical utilization trends.
This performance underlines Cencora’s strategic role as an end-to-end healthcare services company.


Cencora Is Buying Big—But Can Its Acquisition Spree Deliver Massive Long-Term Growth?

<ul>
<li>Cencora Inc., a leading pharmaceutical-centric healthcare solutions provider, reported a robust fiscal 2025 second quarter performance characterized by significant revenue growth and improvement in adjusted earnings per share (EPS).</li>
<li>These results are driven largely by the strategic positioning of Cencora within the healthcare market, particularly in specialty pharmaceuticals and innovative healthcare solutions.</li>
<li>Baptista Research looks to evaluate the different factors that could influence the company's price in the near future and attempts to carry out an independent valuation of the company using a Discounted Cash Flow (DCF) methodology.</li>
</ul>


Cencora Inc., a leading pharmaceutical-centric healthcare solutions provider, reported a robust fiscal 2025 second quarter performance characterized by significant revenue growth and improvement in adjusted earnings per share (EPS).
These results are driven largely by the strategic positioning of Cencora within the healthcare market, particularly in specialty pharmaceuticals and innovative healthcare solutions.
Baptista Research looks to evaluate the different factors that could influence the company's price in the near future and attempts to carry out an independent valuation of the company using a Discounted Cash Flow (DCF) methodology.


Cencora's Billion-Dollar Bet on Specialty & MSO Services Could Reshape Healthcare!

<ul>
<li>Cencora reported a robust performance in the first quarter of fiscal year 2025, showcasing significant growth across various metrics.</li>
<li>The company recorded a revenue increase of 13%, reaching $81.5 billion, driven primarily by strong gains in the U.S. Healthcare Solutions segment.</li>
<li>This growth included a substantial rise in sales of GLP-1 products, which alone saw a 53% year over-year increase.</li>
</ul>


Cencora reported a robust performance in the first quarter of fiscal year 2025, showcasing significant growth across various metrics.
The company recorded a revenue increase of 13%, reaching $81.5 billion, driven primarily by strong gains in the U.S. Healthcare Solutions segment.
This growth included a substantial rise in sales of GLP-1 products, which alone saw a 53% year over-year increase.


Cencora Inc.: Can the MSO Strategy with RCA & OneOncology Drive Sustainable Growth?

<ul>
<li>Cencora, a leading healthcare solutions company, held a discussion reviewing its fiscal 2024 second-quarter results, highlighting both strengths and areas of concern as the organization continues to navigate a complex and evolving market landscape.</li>
<li>The transition announcement of Bob Mauch replacing Steven Collis as CEO presents both an opportunity for continuity and the challenge of strategic execution during leadership changes.</li>
<li>Revenue for the quarter increased by 8%, with an adjusted EPS growth of 9%.</li>
</ul>


Cencora, a leading healthcare solutions company, held a discussion reviewing its fiscal 2024 second-quarter results, highlighting both strengths and areas of concern as the organization continues to navigate a complex and evolving market landscape.
The transition announcement of Bob Mauch replacing Steven Collis as CEO presents both an opportunity for continuity and the challenge of strategic execution during leadership changes.
Revenue for the quarter increased by 8%, with an adjusted EPS growth of 9%.


Cencora Inc.: These Are The 6 Pivotal Factors Impacting Their Performance! - Financial Forecasts

<ul>
<li>Cencora announced during its First Quarter 2024 Earnings, a year-over-year increase in revenue of 15% to over $72 billion, with adjusted earnings per share also increasing year-over-year by 21%.</li>
<li>Recognizing the strong first quarter performance, the company has raised its full-year guidance for fiscal 2024.</li>
<li>The company's performance was fueled by the execution of commercial partnerships and strategic positioning, with teams prioritizing customer-centricity and enhancing service provision.</li>
</ul>


Cencora announced during its First Quarter 2024 Earnings, a year-over-year increase in revenue of 15% to over $72 billion, with adjusted earnings per share also increasing year-over-year by 21%.
Recognizing the strong first quarter performance, the company has raised its full-year guidance for fiscal 2024.
The company's performance was fueled by the execution of commercial partnerships and strategic positioning, with teams prioritizing customer-centricity and enhancing service provision.


Cencora Inc.: These Are The 3 Biggest Challenges In Its Path For Growth! - Key Drivers

United States

Cencora, Inc. operates as a pharmaceutical company. The Company offers end-to-end pharmaceutical commercialization solutions, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to healthcare providers. Cencora distributes its products internationally.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Cencora (COR US)

Cencora Is Buying Big—But Can Its Acquisition Spree Deliver Massive Long-Term Growth?

Cencora, in its fiscal 2025 fourth-quarter and full-year results call, reported strong financial performance supported by growth in its strategic...

Baptista Research

Cencora's Billion-Dollar Bet on Specialty & MSO Services Could Reshape Healthcare!

Cencora Inc., a leading pharmaceutical-centric healthcare solutions provider, reported a robust fiscal 2025 second quarter performance...

Baptista Research

Cencora Inc.: Can the MSO Strategy with RCA & OneOncology Drive Sustainable Growth?

Cencora reported a robust performance in the first quarter of fiscal year 2025, showcasing significant growth across various metrics.

Baptista Research

Cencora Inc.: These Are The 6 Pivotal Factors Impacting Their Performance! - Financial Forecasts

Cencora, a leading healthcare solutions company, held a discussion reviewing its fiscal 2024 second-quarter results, highlighting both strengths...

Baptista Research

Cencora Inc.: These Are The 3 Biggest Challenges In Its Path For Growth! - Key Drivers

Cencora announced during its First Quarter 2024 Earnings, a year-over-year increase in revenue of 15% to over $72 billion, with adjusted earnings...

Baptista Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)